Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)

被引：75

作者：

Figlin, R. A.

Hutson, T. E.

Tomczak, P.

Michaelson, M. D.

Bukowski, R. M.

Negrier, S.

Huang, X.

Kim, S. T.

Chen, I.

Motzer, R. J.

机构：

[1] City Hope Natl Med Ctr, Duarte, CA 91010 USA

[2] Baylor Sammons Canc Ctr Texas Oncol, Dallas, TX USA

[3] Klin Onkologii Oddzial Chemioterapii, Poznan, Poland

[4] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[5] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA

[6] Ctr Leon Berard, F-69373 Lyon, France

[7] Pfizer Global Res & Dev, La Jolla, CA USA

[8] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

关键词：

D O I：

10.1200/jco.2008.26.15_suppl.5024

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5024

引用

页数：1